Novo Nordisk is moving an early-stage Parkinson’s cell therapy into a new biotech home, reflecting continued reshuffling of development assets across cellular and gene-therapy platforms. In a separate item, GSK turned to China-based partners to broaden access to its hepatitis B program, centered on bepirovirsen. Together, the updates show two parallel moves in therapeutic development: companies transferring neurodegeneration programs to align with evolving priorities, and major pharma seeking geographic and commercial pathway coverage through partnerships. For pipeline stakeholders, the Parkinson’s asset relocation signals that early cell-therapy programs may increasingly trade hands as development risk, manufacturing readiness, and strategy converge. The hepatitis B deal points to faster regional access as bepirovirsen’s commercial expansion efforts continue.